A platform of serially transplantable AML PDX models covering subgroups for which no cell lines exist - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

A Series of Transplantable Patient-Derived Xenograft Models for Acute Myeloid Leukemia Subgroups Lacking Established Cell Lines

  • By

  • Binje Vick

  • Vindi Jurinovic

  • Kristina Kuhbandner

  • Lena Lagally

  • Lisa Latzko

  • Chiara Arnreich

  • Gerulf Hänel

  • Amelie Muth

  • Maximilian Schönung

  • Arnold Kloos

  • Maja Rothenberg-Thurley

  • Annika M. Dufour

  • Stephanie Schneider

  • Lesca M. Holdt

  • Liliana Mura

  • Fabian Klein

  • Annette Frank

  • Dhruv Mehra

  • Annika Fröhlich

  • Johannes W. Bagnoli

  • Maya C. André

  • Claudia D. Baldus

  • Martin Carroll

  • Christine Dierks

  • Martin Ebinger

  • Katharina S. Götze

  • Pablo Menéndez

  • Christian Récher

  • Ambrine Sahal

  • Jean-Emmanuel Sarry

  • Christian Thiede

  • Talía Velasco-Hernández

  • Xiaoyan Wei

  • Jan H. Klusmann

  • Wolfgang Enard

  • Michael von Bergwelt-Baildon

  • Wolfgang Hiddemann

  • Klaus H. Metzeler

  • Philipp A. Greif

  • Michael Heuser

  • Daniel B. Lipka

  • Marion Subklewe

  • Sebastian Vosberg

  • Tobias Herold

  • Karsten Spiekermann

  • Irmela Jeremias

  • October 5, 2026

Share

  • 1

    Acute myeloid leukemia (AML) is characterized by the clonal expansion of immature myeloid cells and has a poor prognosis due to frequent relapses.

  • 2

    Patient-derived xenograft (PDX) models are valuable for studying AML, as they replicate the disease's genetic and biological heterogeneity.

  • 3

    The study expanded a collection of serially transplantable PDX models representing AML subgroups that lack established cell lines.

  • 4

    These PDX models facilitate pre-clinical investigations and address fundamental questions in leukemia pathology.

  • 5

    The models are accessible to the research community, with information available through CancerModels.org.

Original Source(s)

A platform of serially transplantable AML PDX models covering subgroups for which no cell lines exist

  • by Binje Vick, Vindi Jurinovic, Kristina Kuhbandner, Lena Lagally, Lisa Latzko, Chiara Arnreich, Gerulf Hänel, Amelie Muth, Maximilian Schönung, Arnold Kloos, Maja Rothenberg-Thurley, Annika M. Dufour, Stephanie Schneider, Lesca M. Holdt, Liliana Mura, Fabian Klein, Annette Frank, Dhruv Mehra, Annika Fröhlich, Johannes W. Bagnoli, Maya C. André, Claudia D. Baldus, Martin Carroll, Christine Dierks, Martin Ebinger, Katharina S. Götze, Pablo Menéndez, Christian Récher, Ambrine Sahal, Jean-Emmanuel Sarry, Christian Thiede, Talía Velasco-Hernández, Xiaoyan Wei, Jan H. Klusmann, Wolfgang Enard, Michael von Bergwelt-Baildon, Wolfgang Hiddemann, Klaus H. Metzeler, Philipp A. Greif, Michael Heuser, Daniel B. Lipka, Marion Subklewe, Sebastian Vosberg, Tobias Herold, Karsten Spiekermann, Irmela Jeremias

  • October 5, 2026

Related Content

Bridging the PSMA PET/CT access gap in prostate cancer: evidence, barriers, and priorities for implementation

Old disease, new twist

Sex, Age, and Tumor Genetics to Inform Risk Stratification in Papillary Thyroid Cancer